爱尔兰爵士制药的去纤苷有什么副作用？

(Defibrotide) is a sodium salt of single-chain polydeoxyribonucleoside. In recent years, studies have confirmed that it is effective in the treatment of hepatic veno-occlusive disease (HVOD), with a remission rate of 42%, and has low toxicity and does not affect systemic coagulation activity. Although the efficacy of this drug has been confirmed by clinical trials, patients may still experience some side effects during actual use.

The most common side effects of Irish Jazz Pharmaceuticals' defibrinoside include hypotension, diarrhea, vomiting, nausea, and nosebleeds. More serious potential side effects include bleeding and allergic reactions. Defibrotide is contraindicated in people who have bleeding complications, are taking blood-thinning medications, or other medications that may affect blood clotting.

The U.S. FDA approved Defitelio (defibrotidesodium) on March 30, 2016, for the treatment of severe hepatic veno-occlusive disease (usually complicated by renal and lung function abnormalities) in adults and children after hematopoietic stem cell transplantation. The FDA also granted it orphan drug status. Defibrotide is marketed by Jazz Pharmaceuticals. Regrettably, it will take some time for defibrotide to be launched in China. Before it is officially launched, patients can first consult some professional and formal overseas medical service organizations in China (such as Medical Companion Travel) to obtain the drug purchase channels for defibrotide.

Jazz Pharmaceuticals was founded in 2003 and is headquartered in Dublin, Ireland, with 885 full-time employees. It is a commercial-stage biopharmaceutical company engaged in the identification, development and commercialization of pharmaceutical products. Since its founding in 2003, it has built a commercial and development organization and assembled products and product candidates that currently include two commercially available products, as well as product candidates in various stages of clinical development. It is now owned by Jazz Pharmaceuticals of Ireland. The successful launch of the drug has also aroused great response in the industry and is worthy of the trust of patients.

Recommended hot articles: /newsDetail/90902.html